Our Products
Vomiq
Product Composition
Packaging Details
Product Description
VOMIQ Syrup
Ondansetron Oral Solution IP 2 mg/5 mL
VOMIQ Syrup is an oral ondansetron formulation containing Ondansetron IP 2 mg in each 5 mL. Ondansetron is a selective 5-HT₃ receptor antagonist used to prevent and control nausea and vomiting in selected clinical settings.
The supplied artwork shows:
- VOMIQ Syrup
- Ondansetron Oral Solution IP 2 mg/5 mL
- 30 mL pack
- Rx
- Flavoured syrup base
- Tartrazine as colour
The product page should describe it as a prescription antiemetic, rather than as a general-purpose medicine for every cause of vomiting.
1. Product Information
| Parameter | Details |
|---|---|
| Brand Name | VOMIQ Syrup |
| Generic Name | Ondansetron |
| Dosage Form | Oral Solution / Syrup |
| Strength | 2 mg/5 mL |
| Active Ingredient | Ondansetron IP |
| Flavoured Base | q.s. |
| Colour | Tartrazine |
| Pack Size | 30 mL |
| Route | Oral |
| Prescription Status | Rx |
| Therapeutic Category | Antiemetic |
| Drug Class | 5-HT₃ receptor antagonist |
The artwork itself establishes the 2 mg/5 mL strength and 30 mL pack size.
2. Composition
Each 5 mL contains:
Ondansetron IP – 2 mg
Flavoured Syrup Base – q.s.
Colour: Tartrazine
Therefore:
| Volume | Ondansetron content |
|---|---|
| 5 mL | 2 mg |
| 10 mL | 4 mg |
| 15 mL | 6 mg |
| 20 mL | 8 mg |
These volume conversions are mathematical equivalents of the labelled 2 mg/5 mL strength and are not dosing recommendations.
3. What is VOMIQ Syrup Used For?
VOMIQ contains ondansetron, an antiemetic medicine used to prevent nausea and vomiting in selected clinical situations.
Established prescribing information includes prevention of:
- Nausea and vomiting associated with highly emetogenic chemotherapy
- Nausea and vomiting associated with moderately emetogenic chemotherapy
- Radiation-associated nausea and vomiting in specified settings
- Postoperative nausea and vomiting
The exact indication for the VOMIQ brand should follow its current approved Indian product information.
Important
Ondansetron does not treat the underlying cause of every episode of vomiting.
Vomiting may result from:
- Gastrointestinal infection
- Food poisoning
- Migraine
- Pregnancy
- Medication adverse effects
- Motion sickness
- Intestinal obstruction
- Appendicitis
- Other acute medical conditions
Persistent or unexplained vomiting therefore requires appropriate clinical assessment.
4. How Does Ondansetron Work?
Ondansetron is a selective serotonin 5-HT₃ receptor antagonist.
During certain conditions, serotonin can stimulate 5-HT₃ receptors in the gastrointestinal tract and central nervous system, contributing to the vomiting reflex.
Ondansetron blocks these receptors.
Simplified mechanism
Serotonin → 5-HT₃ receptor stimulation → vomiting signal
Ondansetron → 5-HT₃ receptor blockade → reduced nausea/vomiting signalling
Ondansetron therefore helps prevent or reduce nausea and vomiting associated with particular triggers.
5. Pharmacological Action
Primary action
5-HT₃ receptor antagonism
Main therapeutic effect
Reduction/prevention of nausea and vomiting
Ondansetron acts on both peripheral and central components of the vomiting pathway.
It is important to note that ondansetron does not stimulate gastrointestinal peristalsis and should not be used as a substitute for treatment of intestinal obstruction or ileus.
6. Therapeutic Benefits
When appropriately prescribed, VOMIQ may help:
- Prevent nausea associated with selected cancer chemotherapy
- Prevent vomiting associated with selected chemotherapy
- Reduce radiation-associated nausea and vomiting in appropriate settings
- Prevent postoperative nausea and vomiting
- Improve oral tolerance when nausea/vomiting is controlled
The clinical benefit depends on the cause of nausea/vomiting and the treatment setting.
7. Suggested Dosage
The artwork establishes the concentration as:
Ondansetron 2 mg/5 mL
However, it does not provide a dosage schedule.
Therefore, the product website should state:
Dosage and duration should be determined by the treating physician according to the patient’s age, indication, clinical condition and response to treatment.
Do not publish a single universal dose such as “5 mL three times daily” for all patients.
Ondansetron dosing varies substantially according to the indication, age and treatment setting. Current prescribing information provides different regimens for chemotherapy-related and postoperative nausea/vomiting.
8. Example of Indication-Specific Dosing
For educational/reference purposes only, current professional labelling provides different regimens depending on the indication.
For example, in moderately emetogenic chemotherapy, one U.S. oral-solution label describes:
- Adults: 8 mg before chemotherapy, followed by another 8 mg 8 hours later, then 8 mg twice daily for 1–2 days.
- Children 4–11 years: 4 mg three times daily in the cited regimen.
- Patients ≥12 years may use the adult regimen for that indication.
These are not universal VOMIQ dosing instructions and should not replace the approved Indian prescribing information.
9. How to Take VOMIQ Syrup
- Shake the bottle if required by the final product instructions.
- Measure the prescribed quantity accurately.
- Use a calibrated measuring device.
- Do not use an ordinary household spoon for accurate dosing.
- Take the medicine according to the physician’s instructions.
- Do not exceed the prescribed amount.
- Do not give the medicine to another person with similar symptoms.
Because the product is a liquid, accurate measurement is particularly important.
10. Missed Dose
If VOMIQ is prescribed on a scheduled basis and a dose is missed:
Take the missed dose according to the prescribing instructions unless it is nearly time for the next dose.
Do not double the next dose unless specifically instructed by a healthcare professional.
For chemotherapy- or procedure-related regimens, the timing of ondansetron can be clinically important, so the treating team should be contacted if a scheduled dose is missed.
11. Common Side Effects
Possible adverse effects include:
Gastrointestinal
- Constipation
- Diarrhoea
- Abdominal discomfort
Nervous system
- Headache
- Dizziness
- Fatigue
Other
- Malaise
- Flushing
- Temporary changes in liver enzyme levels in some patients
Patients should inform their healthcare professional if adverse effects are persistent or troublesome.
12. QT Interval Prolongation
One of the important safety considerations with ondansetron is QT interval prolongation.
Ondansetron has been associated with ECG changes and, rarely, serious ventricular arrhythmias including torsades de pointes.
Particular caution is appropriate in patients with:
- Congenital long-QT syndrome
- Electrolyte abnormalities
- Hypokalaemia
- Hypomagnesaemia
- Congestive heart failure
- Bradyarrhythmias
- Other cardiac rhythm disorders
- Concomitant QT-prolonging medicines
ECG monitoring may be appropriate for patients with significant risk factors.
13. Serotonin Syndrome
Serotonin syndrome has been reported with 5-HT₃ receptor antagonists, particularly when ondansetron is used with other serotonergic medicines.
Potential symptoms include:
- Agitation
- Confusion
- Hallucinations
- Sweating
- Fever
- Rapid heartbeat
- Blood-pressure changes
- Tremor
- Muscle rigidity
- Increased reflexes
- Seizures
The risk is particularly relevant when ondansetron is combined with serotonergic drugs such as certain antidepressants, tramadol, fentanyl and other serotonergic medicines.
Seek urgent medical attention if symptoms suggestive of serotonin syndrome occur.
14. Hypersensitivity and Allergic Reactions
Rare but serious hypersensitivity reactions can occur.
Possible symptoms include:
- Skin rash
- Facial swelling
- Swelling of the lips or tongue
- Difficulty breathing
- Bronchospasm
- Severe dizziness
- Anaphylaxis
Ondansetron should be discontinued and appropriate emergency treatment initiated if a serious hypersensitivity reaction occurs.
15. Important Drug Interactions
Tell the doctor about all medicines being taken.
Particular attention should be given to:
QT-prolonging medicines
Concurrent use may increase the risk of cardiac rhythm abnormalities.
Serotonergic medicines
Examples include:
- SSRIs
- SNRIs
- MAO inhibitors
- Mirtazapine
- Tramadol
- Fentanyl
- Lithium
These may increase concern for serotonin syndrome.
CYP enzyme modifiers
Ondansetron is metabolized through hepatic CYP pathways including CYP3A4, CYP2D6 and CYP1A2. Strong enzyme inducers or inhibitors can alter ondansetron exposure.
16. Important Contraindications
Ondansetron should not be used in patients with:
- Known hypersensitivity to ondansetron or its components
- Concomitant use of apomorphine, according to current U.S. prescribing information
Patients with congenital long-QT syndrome require particular avoidance/caution because of the cardiac electrophysiological risk.
The final Indian product insert should be followed for the exact contraindication list applicable to VOMIQ.
17. Liver Impairment
Ondansetron exposure can be increased in patients with severe hepatic impairment.
Current professional labelling states:
Patients with severe hepatic impairment should not exceed a total daily dose of 8 mg.
For the VOMIQ product page, the safer wording is:
Patients with moderate or severe liver disease should inform their physician before using VOMIQ. Dose adjustment may be required.
18. Kidney Impairment
Ondansetron generally does not require the same degree of dose restriction in renal impairment as in severe hepatic impairment.
Nevertheless, patients with significant kidney disease should inform their physician, particularly when electrolyte abnormalities or multiple medicines are present.
Electrolyte disturbances such as low potassium or magnesium can increase concern regarding QT prolongation.
19. Pregnancy
Ondansetron may be considered in certain pregnancy-related clinical circumstances, but the decision should be made by the treating physician.
Website wording:
Pregnant women should use VOMIQ only on the advice of their healthcare professional.
Do not market VOMIQ as a routine self-treatment for pregnancy-related vomiting.
20. Breastfeeding
Consult a physician before using VOMIQ while breastfeeding.
The clinician can assess the indication, maternal benefit and infant exposure before recommending treatment.
21. Pediatric Use
Ondansetron is used in selected paediatric clinical settings, but paediatric dosing depends on age, indication and clinical situation.
Therefore:
Do not use an adult dose in children. Use VOMIQ in children only according to the physician’s prescribed dose.
Current prescribing information includes specific paediatric regimens for chemotherapy-associated nausea and vomiting.
22. Elderly Patients
Older adults may use ondansetron when clinically indicated, but the physician should consider:
- Cardiac history
- Concomitant medicines
- Electrolyte abnormalities
- Liver function
- Other QT-prolonging medicines
23. Vomiting Due to Intestinal Obstruction
Ondansetron can reduce vomiting without correcting an underlying mechanical obstruction.
Current labelling warns that ondansetron can mask progressive ileus and/or gastric distension in certain settings.
Therefore, persistent vomiting accompanied by:
- Severe abdominal pain
- Abdominal distension
- Inability to pass stool or gas
- Progressive symptoms
requires medical evaluation rather than repeated self-administration of an antiemetic.
24. When to Seek Immediate Medical Attention
Seek urgent medical attention for:
- Difficulty breathing
- Facial/throat swelling
- Severe allergic reaction
- Fainting
- Severe palpitations
- Irregular heartbeat
- Seizures
- Severe confusion or agitation
- High fever with muscle rigidity
- Severe abdominal distension
- Persistent vomiting
- Blood in vomit
Cardiac rhythm abnormalities and serious hypersensitivity reactions are recognized risks requiring prompt evaluation.
25. VOMIQ and Nausea/Vomiting
The vomiting reflex can be triggered by multiple pathways.
Ondansetron primarily works by blocking 5-HT₃ receptors involved in the emetic pathway.
Simplified pathway
Trigger → serotonin release → 5-HT₃ receptor activation → vomiting signal
With ondansetron
Ondansetron → 5-HT₃ receptor blockade → reduced emetic signalling → reduced nausea/vomiting
This mechanism is particularly useful in selected chemotherapy-, radiotherapy- and postoperative settings.
26. Important Product Positioning
For your website, I recommend describing VOMIQ as:
“A prescription ondansetron oral solution for physician-directed prevention and management of nausea and vomiting in selected clinical settings.”
Avoid claims such as:
❌ “Cures vomiting”
❌ “Stops vomiting instantly”
❌ “Works for every type of vomiting”
❌ “100% effective”
❌ “No side effects”
❌ “Safe for everyone”
27. Tartrazine
The supplied artwork specifically identifies:
Colour: Tartrazine
This should be included in the product composition/excipient information.
For patients with known sensitivity to colour additives, the healthcare professional should be informed.
28. Flavoured Syrup Base
The artwork specifies:
Flavoured Syrup Base – q.s.
This means the non-active formulation base is used to provide the required volume and acceptable oral presentation.
The exact flavouring agents are not specified on the supplied artwork, so they should not be individually listed on the website unless confirmed from the approved composition/excipient list.
29. Storage
Store VOMIQ according to the storage instructions on the final approved product label.
General website wording:
- Store in a cool, dry place.
- Protect from excessive heat.
- Protect from direct sunlight.
- Keep the bottle tightly closed.
- Keep out of reach of children.
- Do not use after the expiry date.
The approved marketed pack instructions should take precedence over generic storage wording.
30. Key Product Features
VOMIQ Syrup
- Ondansetron IP 2 mg/5 mL
- Oral solution
- Prescription medicine
- 5-HT₃ receptor antagonist
- Antiemetic
- 30 mL pack
- Flavoured syrup base
- Tartrazine colour
Strength conversion
5 mL = 2 mg Ondansetron
10 mL = 4 mg Ondansetron
15 mL = 6 mg Ondansetron
20 mL = 8 mg Ondansetron
These are strength equivalents, not recommended dosing instructions.
